Nicholas G. Galakatos
Corporate Officer/Principal chez BLACKSTONE INC.
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Gregory Norden | M | 66 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA.
Anthos Therapeutics, Inc.
Anthos Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Anthos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops and commercializes innovative therapies for high-risk cardiovascular patients. It offers MAA868, an antibody directed at Factor XI and XIa, key components of the intrinsic coagulation pathway. The company was founded by Paris Panayiotopoulos, Ari Brettman and Jonathan E. Freeman in 2018 and is headquartered in Cambridge, MA. | 12 ans |
Kiran Reddy | M | 47 |
Clarus Ventures LLC
Clarus Ventures LLC Investment ManagersFinance Clarus Ventures LLC (Clarus Ventures) is a venture capital subsidiary of Blackstone, Inc. founded in 2005 by Nicholas G. Galakatos. The firm is headquartered in Cambridge, Massachusetts.
Blackstone Life Sciences Advisors LLC
Blackstone Life Sciences Advisors LLC Investment ManagersFinance Blackstone Life Sciences Advisors LLC (Blackstone Life Sciences) is a private equity subsidiary of Blackstone, Inc. founded in 2017. The firm is headquartered in New York. | 9 ans |
James Topper | M | 62 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 11 ans |
Glenn Sblendorio | M | 68 | 11 ans | |
William Young | M | 79 |
Clarus Ventures LLC
Clarus Ventures LLC Investment ManagersFinance Clarus Ventures LLC (Clarus Ventures) is a venture capital subsidiary of Blackstone, Inc. founded in 2005 by Nicholas G. Galakatos. The firm is headquartered in Cambridge, Massachusetts.
Blackstone Life Sciences Advisors LLC
Blackstone Life Sciences Advisors LLC Investment ManagersFinance Blackstone Life Sciences Advisors LLC (Blackstone Life Sciences) is a private equity subsidiary of Blackstone, Inc. founded in 2017. The firm is headquartered in New York. | 15 ans |
Ari Brettman | M | 42 |
Clarus Ventures LLC
Clarus Ventures LLC Investment ManagersFinance Clarus Ventures LLC (Clarus Ventures) is a venture capital subsidiary of Blackstone, Inc. founded in 2005 by Nicholas G. Galakatos. The firm is headquartered in Cambridge, Massachusetts.
Blackstone Life Sciences Advisors LLC
Blackstone Life Sciences Advisors LLC Investment ManagersFinance Blackstone Life Sciences Advisors LLC (Blackstone Life Sciences) is a private equity subsidiary of Blackstone, Inc. founded in 2017. The firm is headquartered in New York.
Anthos Therapeutics, Inc.
Anthos Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Anthos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops and commercializes innovative therapies for high-risk cardiovascular patients. It offers MAA868, an antibody directed at Factor XI and XIa, key components of the intrinsic coagulation pathway. The company was founded by Paris Panayiotopoulos, Ari Brettman and Jonathan E. Freeman in 2018 and is headquartered in Cambridge, MA. | 10 ans |
Tuan Ha-Ngoc | M | 72 |
David H. Koch Institute for Integrative Cancer Research
David H. Koch Institute for Integrative Cancer Research Miscellaneous Commercial ServicesCommercial Services David H. Koch Institute for Integrative Cancer Research operates a research facility for cancer cure development. The company was founded in 2007 and is headquartered in Cambridge, MA. | 14 ans |
Michael P. Bailey | M | 58 | 14 ans | |
Heather Behanna | M | 49 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 7 ans |
Thomas Dyrberg | M | 69 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA.
Nuvelution Pharma, Inc.
Nuvelution Pharma, Inc. BiotechnologyHealth Technology Nuvelution Pharma, Inc. provides solutions for R&D companies in the pharmaceutical and biotech industries. The firm leverages its knowledge, experience and relationships in the Pharma and Biotech industries to deploy capital in risk-sharing collaborations with companies where product development can be facilitated by both capital and human resources, making this model an essential tool for pharma and biotech companies to bring products to the market. The company was founded by Sanford S. Zweifach and is headquartered in South San Francisco, CA. | 3 ans |
Jonathan Gray | M | 54 | 32 ans | |
Manoussos Perros | M | 56 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 9 ans |
Nicholas Simon | M | 67 |
Blackstone Life Sciences Advisors LLC
Blackstone Life Sciences Advisors LLC Investment ManagersFinance Blackstone Life Sciences Advisors LLC (Blackstone Life Sciences) is a private equity subsidiary of Blackstone, Inc. founded in 2017. The firm is headquartered in New York.
Clarus Ventures LLC
Clarus Ventures LLC Investment ManagersFinance Clarus Ventures LLC (Clarus Ventures) is a venture capital subsidiary of Blackstone, Inc. founded in 2005 by Nicholas G. Galakatos. The firm is headquartered in Cambridge, Massachusetts.
Nuvelution Pharma, Inc.
Nuvelution Pharma, Inc. BiotechnologyHealth Technology Nuvelution Pharma, Inc. provides solutions for R&D companies in the pharmaceutical and biotech industries. The firm leverages its knowledge, experience and relationships in the Pharma and Biotech industries to deploy capital in risk-sharing collaborations with companies where product development can be facilitated by both capital and human resources, making this model an essential tool for pharma and biotech companies to bring products to the market. The company was founded by Sanford S. Zweifach and is headquartered in South San Francisco, CA. | 19 ans |
Mike Gutch | M | 58 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 7 ans |
Paris Panayiotopoulos | M | 50 |
Clarus Ventures LLC
Clarus Ventures LLC Investment ManagersFinance Clarus Ventures LLC (Clarus Ventures) is a venture capital subsidiary of Blackstone, Inc. founded in 2005 by Nicholas G. Galakatos. The firm is headquartered in Cambridge, Massachusetts.
Blackstone Life Sciences Advisors LLC
Blackstone Life Sciences Advisors LLC Investment ManagersFinance Blackstone Life Sciences Advisors LLC (Blackstone Life Sciences) is a private equity subsidiary of Blackstone, Inc. founded in 2017. The firm is headquartered in New York.
Anthos Therapeutics, Inc.
Anthos Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Anthos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops and commercializes innovative therapies for high-risk cardiovascular patients. It offers MAA868, an antibody directed at Factor XI and XIa, key components of the intrinsic coagulation pathway. The company was founded by Paris Panayiotopoulos, Ari Brettman and Jonathan E. Freeman in 2018 and is headquartered in Cambridge, MA. | 6 ans |
David Hastings | M | 62 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 6 ans |
Heather Elizabeth Preston | M | 58 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 7 ans |
Andrew J. Staples | M | 54 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 9 ans |
Kenneth Bailey | M | 55 | 6 ans | |
Emmett Cunningham | M | 63 |
Clarus Ventures LLC
Clarus Ventures LLC Investment ManagersFinance Clarus Ventures LLC (Clarus Ventures) is a venture capital subsidiary of Blackstone, Inc. founded in 2005 by Nicholas G. Galakatos. The firm is headquartered in Cambridge, Massachusetts.
Blackstone Life Sciences Advisors LLC
Blackstone Life Sciences Advisors LLC Investment ManagersFinance Blackstone Life Sciences Advisors LLC (Blackstone Life Sciences) is a private equity subsidiary of Blackstone, Inc. founded in 2017. The firm is headquartered in New York. | 13 ans |
Kathryn Surace-Smith | F | 65 | 11 ans | |
Jean Rogers | F | - | - | |
David Meek | M | 59 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 5 ans |
Stephen Schwarzman | M | 77 | 39 ans | |
Robert W. Liptak | M | 60 |
Blackstone Life Sciences Advisors LLC
Blackstone Life Sciences Advisors LLC Investment ManagersFinance Blackstone Life Sciences Advisors LLC (Blackstone Life Sciences) is a private equity subsidiary of Blackstone, Inc. founded in 2017. The firm is headquartered in New York.
Clarus Ventures LLC
Clarus Ventures LLC Investment ManagersFinance Clarus Ventures LLC (Clarus Ventures) is a venture capital subsidiary of Blackstone, Inc. founded in 2005 by Nicholas G. Galakatos. The firm is headquartered in Cambridge, Massachusetts. | 19 ans |
Kurt C. Wheeler | M | 71 |
Clarus Ventures LLC
Clarus Ventures LLC Investment ManagersFinance Clarus Ventures LLC (Clarus Ventures) is a venture capital subsidiary of Blackstone, Inc. founded in 2005 by Nicholas G. Galakatos. The firm is headquartered in Cambridge, Massachusetts.
Blackstone Life Sciences Advisors LLC
Blackstone Life Sciences Advisors LLC Investment ManagersFinance Blackstone Life Sciences Advisors LLC (Blackstone Life Sciences) is a private equity subsidiary of Blackstone, Inc. founded in 2017. The firm is headquartered in New York. | 19 ans |
Marcio Souza | M | 45 | 4 ans | |
Robert Gray | M | 47 | 14 ans | |
Jonathan Freeman | M | 56 |
Anthos Therapeutics, Inc.
Anthos Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Anthos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops and commercializes innovative therapies for high-risk cardiovascular patients. It offers MAA868, an antibody directed at Factor XI and XIa, key components of the intrinsic coagulation pathway. The company was founded by Paris Panayiotopoulos, Ari Brettman and Jonathan E. Freeman in 2018 and is headquartered in Cambridge, MA.
Blackstone Life Sciences Advisors LLC
Blackstone Life Sciences Advisors LLC Investment ManagersFinance Blackstone Life Sciences Advisors LLC (Blackstone Life Sciences) is a private equity subsidiary of Blackstone, Inc. founded in 2017. The firm is headquartered in New York. | 6 ans |
Lauren Mastrocola | F | - | 5 ans | |
David Altarac | M | 63 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 5 ans |
Jeffrey Chodakewitz | M | 68 | 3 ans | |
Anthony Riccio | M | - | - | |
Christopher Striano | M | - | - | |
Barry Gertz | M | 72 |
Clarus Ventures LLC
Clarus Ventures LLC Investment ManagersFinance Clarus Ventures LLC (Clarus Ventures) is a venture capital subsidiary of Blackstone, Inc. founded in 2005 by Nicholas G. Galakatos. The firm is headquartered in Cambridge, Massachusetts. | 10 ans |
Emile Farhan | M | - | 12 ans | |
Kelly Ayotte | F | 56 | 5 ans | |
Christine Anderson | F | 47 | 15 ans | |
Alex Nemiroff | M | 45 | 4 ans | |
Steven Petrou | M | - | 9 ans | |
Reginald Brown | M | 56 | 4 ans | |
Robert Langer | M | - |
TransForm Pharmaceuticals, Inc.
TransForm Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology TransForm Pharmaceuticals, Inc. develops and manufactures drugs. It integrates pharmaceutical sciences, materials science and high throughput experimentation by enabling novel technology. The company was founded by Nicholas Galakatos in 1999 and is headquartered in Lexington, MA. | 25 ans |
Karl Hansen | M | - | 4 ans | |
Richard Pasternak | M | 75 |
Anthos Therapeutics, Inc.
Anthos Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Anthos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops and commercializes innovative therapies for high-risk cardiovascular patients. It offers MAA868, an antibody directed at Factor XI and XIa, key components of the intrinsic coagulation pathway. The company was founded by Paris Panayiotopoulos, Ari Brettman and Jonathan E. Freeman in 2018 and is headquartered in Cambridge, MA. | 6 ans |
Daniel Greenberg | M | 83 |
The Reed Institute
| - |
Lindsay Gibson | F | - | 5 ans | |
John Finley | M | 67 | 14 ans | |
Rochelle Lazarus | F | 76 | 11 ans | |
Kenneth Caplan | M | 50 | 27 ans | |
Roger Perlmutter | M | 71 |
The Reed Institute
| - |
Dean Mitchell | M | 68 | 4 ans | |
Gary Kreitzer | M | 69 |
BioMed Realty LP
BioMed Realty LP Real Estate Investment TrustsFinance BioMed Realty LP owns, acquires, develops, redevelops, leases, manages laboratory and office space. The company was founded on April 30, 2004 and is headquartered in San Diego, CA. | 20 ans |
Kirk Malloy | M | 58 | 8 ans | |
Timothy Schoen | M | 56 |
BioMed Realty LP
BioMed Realty LP Real Estate Investment TrustsFinance BioMed Realty LP owns, acquires, develops, redevelops, leases, manages laboratory and office space. The company was founded on April 30, 2004 and is headquartered in San Diego, CA. | 8 ans |
Jim Breyer | M | 62 | 8 ans | |
Dennis J. Henner | M | 72 |
Clarus Ventures LLC
Clarus Ventures LLC Investment ManagersFinance Clarus Ventures LLC (Clarus Ventures) is a venture capital subsidiary of Blackstone, Inc. founded in 2005 by Nicholas G. Galakatos. The firm is headquartered in Cambridge, Massachusetts.
The Reed Institute
| 14 ans |
Elisha Finney | F | 62 | 7 ans | |
John Maraganore | M | 60 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 8 ans |
Michael Chae | M | 55 | 27 ans | |
William Parrett | M | 77 | 17 ans | |
Lionel Yves Assant | M | 52 | - | |
Joseph Baratta | M | 53 | 26 ans | |
Kathy Galante | F | - | 11 ans | |
Vikrant Sawhney | M | 54 | 17 ans | |
Ruth Porat | F | 66 | 4 ans | |
Robert DeBenedetto | M | - |
Clarus Ventures LLC
Clarus Ventures LLC Investment ManagersFinance Clarus Ventures LLC (Clarus Ventures) is a venture capital subsidiary of Blackstone, Inc. founded in 2005 by Nicholas G. Galakatos. The firm is headquartered in Cambridge, Massachusetts.
Blackstone Life Sciences Advisors LLC
Blackstone Life Sciences Advisors LLC Investment ManagersFinance Blackstone Life Sciences Advisors LLC (Blackstone Life Sciences) is a private equity subsidiary of Blackstone, Inc. founded in 2017. The firm is headquartered in New York. | 8 ans |
Peter Koffler | M | - | 12 ans | |
Charles Custeau | M | - | 3 ans | |
David Sabatini | M | - |
David H. Koch Institute for Integrative Cancer Research
David H. Koch Institute for Integrative Cancer Research Miscellaneous Commercial ServicesCommercial Services David H. Koch Institute for Integrative Cancer Research operates a research facility for cancer cure development. The company was founded in 2007 and is headquartered in Cambridge, MA. | - |
Stuart Grant | M | 56 | - | |
Dwight Scott | M | 60 | - | |
Menes Chee | M | 46 | 15 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Scott Requadt | M | 56 |
Clarus Ventures LLC
Clarus Ventures LLC Investment ManagersFinance Clarus Ventures LLC (Clarus Ventures) is a venture capital subsidiary of Blackstone, Inc. founded in 2005 by Nicholas G. Galakatos. The firm is headquartered in Cambridge, Massachusetts.
TransForm Pharmaceuticals, Inc.
TransForm Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology TransForm Pharmaceuticals, Inc. develops and manufactures drugs. It integrates pharmaceutical sciences, materials science and high throughput experimentation by enabling novel technology. The company was founded by Nicholas Galakatos in 1999 and is headquartered in Lexington, MA. | 22 ans |
Wayne D. Burns | M | 67 | 10 ans | |
Hollings Renton | M | 77 | 11 ans | |
Suzanne Fleming | F | 63 |
TransForm Pharmaceuticals, Inc.
TransForm Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology TransForm Pharmaceuticals, Inc. develops and manufactures drugs. It integrates pharmaceutical sciences, materials science and high throughput experimentation by enabling novel technology. The company was founded by Nicholas Galakatos in 1999 and is headquartered in Lexington, MA. | 10 ans |
Russell C. Hirsch | M | 62 | 11 ans | |
William Lis | M | 59 | 11 ans | |
Mardi Dier | F | 60 | 14 ans | |
Bruce Peacock | M | 72 | 4 ans | |
Finny Kuruvilla | M | 49 |
Clarus Ventures LLC
Clarus Ventures LLC Investment ManagersFinance Clarus Ventures LLC (Clarus Ventures) is a venture capital subsidiary of Blackstone, Inc. founded in 2005 by Nicholas G. Galakatos. The firm is headquartered in Cambridge, Massachusetts. | - |
Donna M. Radzik | M | - | - | |
Arlene Morris | F | 72 | 8 ans | |
Mary Fenton | F | 60 | - | |
Ken Bate | M | 73 | 16 ans | |
Henri A. Termeer | M | 78 | 6 ans | |
Anna Protopapas | F | 59 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 17 ans |
John Curnutte | M | 72 | 8 ans | |
Steven Love | M | 55 | 3 ans | |
Robert Scarborough | M | - | 3 ans | |
Joseph Vittiglio | M | 52 | 8 ans | |
Raju S. Kucherlapati | M | 81 | 19 ans | |
Laura Brege | F | 66 | 5 ans | |
Elan Ezickson | M | 60 | 10 ans | |
John P. Walker | M | 75 | - | |
Dennis Fenton | M | 72 | - | |
Douglas Cole | M | 63 | 10 ans | |
Henry Ward Wolff | M | 75 | 13 ans | |
John Johnson | M | 66 | - | |
Matthew D. Dallas | M | 49 | 4 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 100 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Nicholas G. Galakatos
- Réseau Personnel